27 results on '"Viiri LE"'
Search Results
2. Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis
- Author
-
Abboud, S, Viiri, LE, Lütjohann, D, Goebeler, S, Luoto, T, Friedrichs, S, Desfontaines, P, Gazagnes, MD, Laloux, P, Peeters, Anna, Seeldrayers, P, Lehtimaki, T, Karhunen, P, Pandolfo, M, Laaksonen, R, Abboud, S, Viiri, LE, Lütjohann, D, Goebeler, S, Luoto, T, Friedrichs, S, Desfontaines, P, Gazagnes, MD, Laloux, P, Peeters, Anna, Seeldrayers, P, Lehtimaki, T, Karhunen, P, Pandolfo, M, and Laaksonen, R
- Published
- 2008
3. Improvements in Maturity and Stability of 3D iPSC-Derived Hepatocyte-like Cell Cultures.
- Author
-
Suominen S, Hyypijev T, Venäläinen M, Yrjänäinen A, Vuorenpää H, Lehti-Polojärvi M, Räsänen M, Seppänen A, Hyttinen J, Miettinen S, Aalto-Setälä K, and Viiri LE
- Subjects
- Humans, Endothelial Cells, Hepatocytes metabolism, Liver, Cell Culture Techniques methods, Induced Pluripotent Stem Cells metabolism
- Abstract
Induced pluripotent stem cell (iPSC) technology enables differentiation of human hepatocytes or hepatocyte-like cells (iPSC-HLCs). Advances in 3D culturing platforms enable the development of more in vivo-like liver models that recapitulate the complex liver architecture and functionality better than traditional 2D monocultures. Moreover, within the liver, non-parenchymal cells (NPCs) are critically involved in the regulation and maintenance of hepatocyte metabolic function. Thus, models combining 3D culture and co-culturing of various cell types potentially create more functional in vitro liver models than 2D monocultures. Here, we report the establishment of 3D cultures of iPSC-HLCs alone and in co-culture with human umbilical vein endothelial cells (HUVECs) and adipose tissue-derived mesenchymal stem/stromal cells (hASCs). The 3D cultures were performed as spheroids or on microfluidic chips utilizing various biomaterials. Our results show that both 3D spheroid and on-chip culture enhance the expression of mature liver marker genes and proteins compared to 2D. Among the spheroid models, we saw the best functionality in iPSC-HLC monoculture spheroids. On the contrary, in the chip system, the multilineage model outperformed the monoculture chip model. Additionally, the optical projection tomography (OPT) and electrical impedance tomography (EIT) system revealed changes in spheroid size and electrical conductivity during spheroid culture, suggesting changes in cell-cell connections. Altogether, the present study demonstrates that iPSC-HLCs can successfully be cultured in 3D as spheroids and on microfluidic chips, and co-culturing iPSC-HLCs with NPCs enhances their functionality. These 3D in vitro liver systems are promising human-derived platforms usable in various liver-related studies, specifically when using patient-specific iPSCs.
- Published
- 2023
- Full Text
- View/download PDF
4. Coronary artery disease patient-derived iPSC-hepatocytes have distinct miRNA profile that may alter lipid metabolism.
- Author
-
Alexanova A, Raitoharju E, Valtonen J, Aalto-Setälä K, and Viiri LE
- Subjects
- Humans, Lipid Metabolism genetics, Hepatocytes metabolism, MicroRNAs genetics, MicroRNAs metabolism, Coronary Artery Disease genetics, Coronary Artery Disease metabolism, Induced Pluripotent Stem Cells metabolism, Plaque, Atherosclerotic metabolism, Myocardial Ischemia metabolism
- Abstract
Metabolic dysfunction, partly driven by altered liver function, predisposes to coronary artery disease (CAD), but the role of liver in vulnerable atherosclerotic plaque development remains unclear. Here we produced hepatocyte-like cells (HLCs) from 27 induced pluripotent stem cell (iPSC) lines derived from 15 study subjects with stable CAD (n = 5), acute CAD (n = 5) or healthy controls (n = 5). We performed a miRNA microarray screening throughout the differentiation, as well as compared iPSC-HLCs miRNA profiles of the patient groups to identify miRNAs involved in the development of CAD. MicroRNA profile changed during differentiation and started to resemble that of the primary human hepatocytes. In the microarray, 35 and 87 miRNAs were statistically significantly deregulated in the acute and stable CAD patients, respectively, compared to controls. Down-regulation of miR-149-5p, -92a-3p and -221-3p, and up-regulation of miR-122-5p was verified in the stable CAD patients when compared to other groups. The predicted targets of deregulated miRNAs were enriched in pathways connected to insulin signalling, inflammation and lipid metabolism. The iPSC-HLCs derived from stable CAD patients with extensive lesions had a distinct genetic miRNA profile possibly linked to metabolic dysfunction, potentially explaining the susceptibility to developing CAD. The iPSC-HLCs from acute CAD patients with only the acute rupture in otherwise healthy coronaries did not present a distinct miRNA profile, suggesting that hepatic miRNAs do not explain susceptibility to plaque rupture., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
5. Retrieval of the conductivity spectrum of tissues in vitro with novel multimodal tomography.
- Author
-
Lehti-Polojärvi M, Räsänen MJ, Viiri LE, Vuorenpää H, Miettinen S, Seppänen A, and Hyttinen J
- Subjects
- Algorithms, Electric Conductivity, Electric Impedance, Phantoms, Imaging, Tomography, X-Ray Computed, Tomography methods, Tomography, Optical
- Abstract
Objective: Imaging of tissue engineered three-dimensional (3D) specimens is challenging due to their thickness. We propose a novel multimodal imaging technique to obtain multi-physical 3D images and the electrical conductivity spectrum of tissue engineered specimens in vitro ., Approach: We combine simultaneous recording of rotational multifrequency electrical impedance tomography (R-mfEIT) with optical projection tomography (OPT). Structural details of the specimen provided by OPT are used here as geometrical priors for R-mfEIT., Main Results: This data fusion enables accurate retrieval of the conductivity spectrum of the specimen. We demonstrate experimentally the feasibility of the proposed technique using a potato phantom, adipose and liver tissues, and stem cells in biomaterial spheroids. The results indicate that the proposed technique can distinguish between viable and dead tissues and detect the presence of stem cells., Significance: This technique is expected to become a valuable tool for monitoring tissue engineered specimens' growth and viability in vitro ., (Creative Commons Attribution license.)
- Published
- 2021
- Full Text
- View/download PDF
6. Methylation status of nc886 epiallele reflects periconceptional conditions and is associated with glucose metabolism through nc886 RNAs.
- Author
-
Marttila S, Viiri LE, Mishra PP, Kühnel B, Matias-Garcia PR, Lyytikäinen LP, Ceder T, Mononen N, Rathmann W, Winkelmann J, Peters A, Kähönen M, Hutri-Kähönen N, Juonala M, Aalto-Setälä K, Raitakari O, Lehtimäki T, Waldenberger M, and Raitoharju E
- Subjects
- Adult, DNA Methylation genetics, DNA Methylation physiology, Epigenesis, Genetic, Humans, Glucose Metabolism Disorders genetics, RNA, Untranslated analysis
- Abstract
Background: Non-coding RNA 886 (nc886) is coded from a maternally inherited metastable epiallele. We set out to investigate the determinants and dynamics of the methylation pattern at the nc886 epiallele and how this methylation status associates with nc886 RNA expression. Furthermore, we investigated the associations between the nc886 methylation status or the levels of nc886 RNAs and metabolic traits in the YFS and KORA cohorts. The association between nc886 epiallele methylation and RNA expression was also validated in induced pluripotent stem cell (iPSC) lines., Results: We confirm that the methylation status of the nc886 epiallele is mostly binomial, with individuals displaying either a non- or hemi-methylated status, but we also describe intermediately and close to fully methylated individuals. We show that an individual's methylation status is associated with the mother's age and socioeconomic status, but not with the individual's own genetics. Once established, the methylation status of the nc886 epiallele remains stable for at least 25 years. This methylation status is strongly associated with the levels of nc886 non-coding RNAs in serum, blood, and iPSC lines. In addition, nc886 methylation status associates with glucose and insulin levels during adolescence but not with the indicators of glucose metabolism or the incidence of type 2 diabetes in adulthood. However, the nc886-3p RNA levels also associate with glucose metabolism in adulthood., Conclusions: These results indicate that nc886 metastable epiallele methylation is tuned by the periconceptional conditions and it associates with glucose metabolism through the expression of the ncRNAs coded in the epiallele region., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
7. Different rates of flux through the biosynthetic pathway for long-chain versus very-long-chain sphingolipids.
- Author
-
Zelnik ID, Volpert G, Viiri LE, Kauhanen D, Arazi T, Aalto-Setälä K, Laaksonen R, and Futerman AH
- Subjects
- Biosynthetic Pathways, Animals, Fatty Acids metabolism, Fatty Acids biosynthesis, Fatty Acids chemistry, Humans, Sphingolipids biosynthesis, Sphingolipids metabolism, Sphingolipids chemistry, Ceramides metabolism, Ceramides chemistry
- Abstract
The backbone of all sphingolipids (SLs) is a sphingoid long-chain base (LCB) to which a fatty acid is N -acylated. Considerable variability exists in the chain length and degree of saturation of both of these hydrophobic chains, and recent work has implicated ceramides with different LCBs and N -acyl chains in distinct biological processes; moreover, they may play different roles in disease states and possibly even act as prognostic markers. We now demonstrate that the half-life, or turnover rate, of ceramides containing diverse N -acyl chains is different. By means of a pulse-labeling protocol using stable-isotope, deuterated free fatty acids, and following their incorporation into ceramide and downstream SLs, we show that very-long-chain (VLC) ceramides containing C24:0 or C24:1 fatty acids turn over much more rapidly than long-chain (LC) ceramides containing C16:0 or C18:0 fatty acids due to the more rapid metabolism of the former into VLC sphingomyelin and VLC hexosylceramide. In contrast, d16:1 and d18:1 ceramides show similar rates of turnover, indicating that the length of the sphingoid LCB does not influence the flux of ceramides through the biosynthetic pathway. Together, these data demonstrate that the N -acyl chain length of SLs may not only affect membrane biophysical properties but also influence the rate of metabolism of SLs so as to regulate their levels and perhaps their biological functions., Competing Interests: Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2020 Zelnik et al.)
- Published
- 2020
- Full Text
- View/download PDF
8. hiPSC-derived hepatocytes closely mimic the lipid profile of primary hepatocytes: A future personalised cell model for studying the lipid metabolism of the liver.
- Author
-
Kiamehr M, Alexanova A, Viiri LE, Heiskanen L, Vihervaara T, Kauhanen D, Ekroos K, Laaksonen R, Käkelä R, and Aalto-Setälä K
- Subjects
- Cell Shape, Chromatography, Gas, Fatty Acids metabolism, Gene Expression Regulation, Hep G2 Cells, Humans, Lipidomics methods, Lysophospholipids metabolism, Mass Spectrometry, Phenotype, Primary Cell Culture, Cell Differentiation, Hepatocytes metabolism, Induced Pluripotent Stem Cells metabolism, Lipid Metabolism genetics
- Abstract
Hepatocyte-like cells (HLCs) differentiated from human-induced pluripotent stem cells offer an alternative platform to primary human hepatocytes (PHHs) for studying the lipid metabolism of the liver. However, despite their great potential, the lipid profile of HLCs has not yet been characterized. Here, we comprehensively studied the lipid profile and fatty acid (FA) metabolism of HLCs and compared them with the current standard hepatocyte models: HepG2 cells and PHHs. We differentiated HLCs by five commonly used methods from three cell lines and thoroughly characterized them by gene and protein expression. HLCs generated by each method were assessed for their functionality and the ability to synthesize, elongate, and desaturate FAs. In addition, lipid and FA profiles of HLCs were investigated by both mass spectrometry and gas chromatography and then compared with the profiles of PHHs and HepG2 cells. HLCs resembled PHHs by expressing hepatic markers: secreting albumin, lipoprotein particles, and urea, and demonstrating similarities in their lipid and FA profile. Unlike HepG2 cells, HLCs contained low levels of lysophospholipids similar to the content of PHHs. Furthermore, HLCs were able to efficiently use the exogenous FAs available in their medium and simultaneously modify simple lipids into more complex ones to fulfill their needs. In addition, we propose that increasing the polyunsaturated FA supply of the culture medium may positively affect the lipid profile and functionality of HLCs. In conclusion, our data showed that HLCs provide a functional and relevant model to investigate human lipid homeostasis at both molecular and cellular levels., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
9. Extensive reprogramming of the nascent transcriptome during iPSC to hepatocyte differentiation.
- Author
-
Viiri LE, Rantapero T, Kiamehr M, Alexanova A, Oittinen M, Viiri K, Niskanen H, Nykter M, Kaikkonen MU, and Aalto-Setälä K
- Subjects
- Humans, Induced Pluripotent Stem Cells metabolism, MicroRNAs genetics, RNA, Long Noncoding genetics, Cellular Reprogramming genetics, Hepatocytes cytology, Induced Pluripotent Stem Cells cytology, Transcriptome
- Abstract
Hepatocyte-like cells (HLCs) derived from induced pluripotent stem cells (iPSCs) provide a renewable source of cells for drug discovery, disease modelling and cell-based therapies. Here, by using GRO-Seq we provide the first genome-wide analysis of the nascent RNAs in iPSCs, HLCs and primary hepatocytes to extend our understanding of the transcriptional changes occurring during hepatic differentiation process. We demonstrate that a large fraction of hepatocyte-specific genes are regulated at transcriptional level and identify hundreds of differentially expressed non-coding RNAs (ncRNAs), including primary miRNAs (pri-miRNAs) and long non-coding RNAs (lncRNAs). Differentiation induced alternative transcription start site (TSS) usage between the cell types as evidenced for miR-221/222 and miR-3613/15a/16-1 clusters. We demonstrate that lncRNAs and coding genes are tightly co-expressed and could thus be co-regulated. Finally, we identified sets of transcriptional regulators that might drive transcriptional changes during hepatocyte differentiation. These included RARG, E2F1, SP1 and FOXH1, which were associated with the down-regulated transcripts, and hepatocyte-specific TFs such as FOXA1, FOXA2, HNF1B, HNF4A and CEBPA, as well as RXR, PPAR, AP-1, JUNB, JUND and BATF, which were associated with up-regulated transcripts. In summary, this study clarifies the role of regulatory ncRNAs and TFs in differentiation of HLCs from iPSCs.
- Published
- 2019
- Full Text
- View/download PDF
10. Lipidomic profiling of patient-specific iPSC-derived hepatocyte-like cells.
- Author
-
Kiamehr M, Viiri LE, Vihervaara T, Koistinen KM, Hilvo M, Ekroos K, Käkelä R, and Aalto-Setälä K
- Subjects
- Animals, Cell Differentiation, Cell Line, Cholesterol Esters metabolism, Endoderm cytology, Fatty Acids, Unsaturated metabolism, Gene Expression Regulation, Humans, Mice, Phosphatidylcholines metabolism, Sphingolipids metabolism, Hepatocytes cytology, Hepatocytes metabolism, Induced Pluripotent Stem Cells cytology, Induced Pluripotent Stem Cells metabolism, Lipid Metabolism genetics, Metabolomics methods
- Abstract
Hepatocyte-like cells (HLCs) differentiated from human induced pluripotent stem cells (iPSCs) offer an alternative model to primary human hepatocytes to study lipid aberrations. However, the detailed lipid profile of HLCs is yet unknown. In the current study, functional HLCs were differentiated from iPSCs generated from dermal fibroblasts of three individuals by a three-step protocol through the definitive endoderm (DE) stage. In parallel, detailed lipidomic analyses as well as gene expression profiling of a set of lipid-metabolism-related genes were performed during the entire differentiation process from iPSCs to HLCs. Additionally, fatty acid (FA) composition of the cell culture media at different stages was determined. Our results show that major alterations in the molecular species of lipids occurring during DE and early hepatic differentiation stages mainly mirror the quality and quantity of the FAs supplied in culture medium at each stage. Polyunsaturated phospholipids and sphingolipids with a very long FA were produced in the cells at a later stage of differentiation. This work uncovers the previously unknown lipid composition of iPSC-HLCs and its alterations during the differentiation in conjunction with the expression of key lipid-associated genes. Together with biochemical, functional and gene expression measurements, the lipidomic analyses allowed us to improve our understanding of the concerted influence of the exogenous metabolite supply and cellular biosynthesis essential for iPSC-HLC differentiation and function. Importantly, the study describes in detail a cell model that can be applied in exploring, for example, the lipid metabolism involved in the development of fatty liver disease or atherosclerosis., Competing Interests: Competing interestsT.V., K.M.K. and M.H. are employed by Zora Biosciences, Espoo, Finland. K.E. is currently employed by Lipidomics Consulting, Espoo, Finland. Other authors declare no conflict of interest., (© 2017. Published by The Company of Biologists Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
11. Multi-analyte profiling in human carotid atherosclerosis uncovers pro-inflammatory macrophage programming in plaques.
- Author
-
Shalhoub J, Viiri LE, Cross AJ, Gregan SM, Allin DM, Astola N, Franklin IJ, Davies AH, and Monaco C
- Subjects
- Aged, Carotid Artery Diseases immunology, Carotid Artery Diseases surgery, Carotid Stenosis immunology, Carotid Stenosis metabolism, Carotid Stenosis surgery, Chemokines metabolism, Colony-Stimulating Factors metabolism, Cytokines metabolism, Endarterectomy, Carotid, Female, Humans, Macrophages immunology, Male, Matrix Metalloproteinases metabolism, Middle Aged, Protein Array Analysis, Tissue Inhibitor of Metalloproteinases metabolism, Carotid Artery Diseases metabolism, Inflammation Mediators metabolism, Macrophages metabolism
- Abstract
Molecular characterisation of vulnerable atherosclerosis is necessary for targeting functional imaging and plaque-stabilising therapeutics. Inflammation has been linked to atherogenesis and the development of high-risk plaques. We set to quantify cytokine, chemokine and matrix metalloproteinase (MMP) protein production in cells derived from carotid plaques to map the inflammatory milieu responsible for instability. Carotid endarterectomies from carefully characterised symptomatic (n=35) and asymptomatic (n=32) patients were enzymatically dissociated producing mixed cell type atheroma cell suspensions which were cultured for 24 hours. Supernatants were interrogated for 45 analytes using the Luminex 100 platform. Twenty-nine of the 45 analytes were reproducibly detectable in the majority of donors. The in vitro production of a specific network of mediators was found to be significantly higher in symptomatic than asymptomatic plaques, including: tumour necrosis factor α, interleukin (IL) 1β, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), CCL5, CCL20, CXCL9, matrix metalloproteinase (MMP)-3 and MMP-9. Ingenuity pathway analysis of differentially expressed analytes between symptomatic and asymptomatic patients identified a number of key biological pathways (p< 10(-25)). In conclusion, the carotid artery plaque culprit of ischaemic neurological symptoms is characterised by an inflammatory milieu favouring inflammatory cell recruitment and pro-inflammatory macrophage polarisation.
- Published
- 2016
- Full Text
- View/download PDF
12. A Comparative View on Easy to Deploy non-Integrating Methods for Patient-Specific iPSC Production.
- Author
-
Manzini S, Viiri LE, Marttila S, and Aalto-Setälä K
- Subjects
- Cell Proliferation, Cells, Cultured, Electroporation, Fibroblasts cytology, Genetic Vectors, Humans, Lipids pharmacology, Sendai virus metabolism, Transfection methods, Cellular Reprogramming genetics, Cellular Reprogramming Techniques methods, Induced Pluripotent Stem Cells cytology
- Abstract
Induced pluripotent stem cells (iPSCs) are routinely produced from dermal fibroblasts, with potential applications ranging from in vitro disease models to drug discovery and regenerative medicine. The need of eliminating the remaining reprogramming factors after iPSC production spurred the development of non-integrating viruses such as Sendai and other methods to deliver episomal vectors, which are progressively lost upon cell division. We compared four widespread methods (Sendai virus, Nucleofector, Neon transfection system and Lipofectamine 3000) to generate integration-free iPSC lines from primary human dermal fibroblasts (hDF) of three patients. Furthermore, we performed extensive characterization of the iPSC lines. We were able to produce iPSC lines with all tested methods with variable efficiency. Sendai virus method achieved the overall highest reprogramming rate, followed by electroporation-based methods Nucleofector and Neon transfection systems. Chemical-based Lipofectamine 3000 delivery resulted in the lowest number of iPSC colonies. We found the reprogramming rate to be intrinsically dependent on the individual hDFs but the amenability of each hDF to reprogramming showed consistency between methods. Regardless of the reprogramming strategy, iPSCs obtained did not reveal any significant differences in their morphology, expression of pluripotency markers, EB formation, karyotype or gene expression profiles.
- Published
- 2015
- Full Text
- View/download PDF
13. Interleukin-6 and microRNA profiles induced by oral bacteria in human atheroma derived and healthy smooth muscle cells.
- Author
-
Pessi T, Viiri LE, Raitoharju E, Astola N, Seppälä I, Waldenberger M, Lounatmaa K, Davies AH, Lehtimäki T, Karhunen PJ, and Monaco C
- Abstract
Background: Atherosclerosis is an inflammatory disease with possible contributions from bacterial antigens. We aimed to investigate the role of oral bacteria as inducers of inflammatory cascades in smooth muscle cells from carotid endarterectomy patients (AthSMCs) and healthy controls (HSMCs)., Findings: Inactivated Streptococcus mitis, S. sanguinis, S. gorgonii, Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were used to stimulate inflammation in HSMCs and AthSMCs. Tumor necrosis factor-α (TNFα) was used as a positive control in all stimulations. Interleukin-6 (IL-6) levels were determined from cell culture supernatants and microRNA expression profiles from cells after 24 h of bacterial stimulation. Genome wide expression (GWE) analyses were performed after 5 h stimulation. All studied bacteria induced pro inflammatory IL-6 production in both SMCs. The most powerful inducer of IL-6 was A. actinomycetemcomitans (p < 0.001). Of the 84 studied miRNAs, expression of 9 miRNAs differed significantly (p ≤ 0.001) between HSMCs and AthSMCs stimulated with inactivated bacteria or TNFα. The data was divided into two groups: high IL-6 producers (A. actinomytectemcomititans and TNFα) and low IL-6 producers (streptococcal strains and P. gingivalis). The expression of 4 miRNAs (miR-181-5p, -186-5p, -28-5p and -155-5p) differed statistically significantly (p < 0.001) between healthy HSMCs and AthSMCs in the low IL-6 producer group. According to multidimensional scaling, two gene expression clusters were seen: one in HSMCs and one AthSMCs., Conclusions: Our results suggest that inactivated oral bacteria induce inflammation that is differently regulated in healthy and atherosclerotic SMCs.
- Published
- 2015
- Full Text
- View/download PDF
14. MicroRNAs in atherosclerosis.
- Author
-
Hosin AA, Prasad A, Viiri LE, Davies AH, and Shalhoub J
- Subjects
- Animals, Atherosclerosis diagnosis, Atherosclerosis genetics, Atherosclerosis immunology, Atherosclerosis therapy, Disease Progression, Endothelium, Vascular immunology, Endothelium, Vascular pathology, Gene Expression Regulation, Genetic Predisposition to Disease, Genetic Therapy, Humans, MicroRNAs genetics, MicroRNAs therapeutic use, Muscle, Smooth, Vascular immunology, Muscle, Smooth, Vascular pathology, Phenotype, Prognosis, Risk Factors, Signal Transduction, Atherosclerosis metabolism, Endothelium, Vascular metabolism, MicroRNAs metabolism, Muscle, Smooth, Vascular metabolism
- Abstract
Micro-ribonucleic acids (miRNAs) are a class of endogenous non-coding ribonucleic acids that regulate gene expression. MiRNAs have been shown to act as key regulators in the vascular system, with wide-ranging physio-pathological effects. Atherosclerotic disease is a leading cause of morbidity and mortality worldwide. This review presents current knowledge on miRNAs implicated in atherosclerosis susceptibility, development and progression. They are involved in cell phenotype switching, response to shear stress, cell senescence, adhesion molecule expression, macrophage response to oxidised low-density lipoprotein, Toll-like receptor 4 expression, neointimal lesion formation, plaque angiogenesis and cellular cholesterol homeostasis. Clinically, early work has demonstrated the utility of miRNAs for differentiating patients with arterial disease from controls and predicting future cardiac events; this highlights potential diagnostic and prognostic roles. MiRNA involvement in the crucial stages of atherosclerosis promises new hope in treating arterial disease. However, issues regarding multiple miRNA targets, stability and delivery continue to present challenges., (© 2014 S. Karger AG, Basel.)
- Published
- 2014
- Full Text
- View/download PDF
15. Smooth muscle cells in human atherosclerosis: proteomic profiling reveals differences in expression of Annexin A1 and mitochondrial proteins in carotid disease.
- Author
-
Viiri LE, Full LE, Navin TJ, Begum S, Didangelos A, Astola N, Berge RK, Seppälä I, Shalhoub J, Franklin IJ, Perretti M, Lehtimäki T, Davies AH, Wait R, and Monaco C
- Subjects
- Adult, Aldehyde Dehydrogenase metabolism, Aldehyde Dehydrogenase, Mitochondrial, Animals, Carotid Artery Diseases pathology, Cells, Cultured, Cytokines metabolism, Gene Expression, Humans, Mice, Mice, Knockout, Mitochondria, Muscle metabolism, Mitochondrial Proton-Translocating ATPases metabolism, Muscle, Smooth, Vascular pathology, Oxidation-Reduction, Peroxiredoxins metabolism, Phenotype, Principal Component Analysis, Proteomics, Annexin A1 metabolism, Atherosclerosis pathology, Carotid Artery Diseases metabolism, Mitochondrial Proteins metabolism, Myocytes, Smooth Muscle metabolism, Proteome metabolism
- Abstract
Smooth muscle cells (SMC) contribute to the development and stability of atherosclerotic lesions. The molecular mechanisms that mediate their properties are incompletely defined. We employed proteomics and in vitro functional assays to identify the unique characteristics of intimal SMC isolated from human carotid endarterectomy specimens and medial SMC from thoracic aortas and carotids. We verified our findings in the Tampere Vascular Study. Human atheroma-derived SMC exhibit decreased expression of mitochondrial proteins ATP Synthase subunit-beta and Aldehyde dehydrogenase 2, and decreased mitochondrial activity when compared to control SMC. Moreover, a comparison between plaque-derived SMC isolated from patients with or without recent acute cerebrovascular symptoms uncovered an increase in Annexin A1, an endogenous anti-inflammatory protein, in the asymptomatic group. The deletion of Annexin A1 or the blockade of its signaling in SMC resulted in increased cytokine production at baseline and after stimulation with the pro-inflammatory cytokine Tumor Necrosis Factor α. In summary, our proteomics and biochemical analysis revealed mitochondrial damage in human plaque-derived SMC as well as a role of Annexin A1 in reducing the production of pro-inflammatory mediators in SMC., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
16. Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study.
- Author
-
Hernesniemi JA, Karhunen PJ, Oksala N, Kähönen M, Levula M, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Hurme M, and Lehtimäki T
- Subjects
- Adult, Aged, Alleles, Autopsy, Coronary Disease mortality, Death, Sudden, Cardiac epidemiology, Finland epidemiology, Gene Expression Regulation, Genetic Predisposition to Disease, Genotype, Hospitalization, Humans, Hypertension mortality, Male, Middle Aged, Coronary Disease genetics, Death, Sudden, Cardiac etiology, Hypertension genetics, Interleukin-18 genetics, Polymorphism, Genetic, Promoter Regions, Genetic genetics
- Abstract
Aims: The interleukin 18 (IL-18) gene has a single nucleotide promoter region (-137) G-to-C polymorphism (rs187238) which leads to attenuated transcriptional activity of the gene and to lower production of pro-atherogenic IL-18. The C allele of this polymorphism is associated with a lower risk of sudden cardiac death (SCD). We examined the process by which this polymorphism alters the risk of SCD and coronary artery disease (CAD) by analysing the interactions between this polymorphism and environmental factors., Methods and Results: TaqMan 5' nuclease assay was used to genotype the study population of the Helsinki Sudden Death Study, comprising medicolegal autopsies of 700 men. According to adjusted logistic regression analysis, there was a significant interaction between IL-18 genotype and hypertension impacting on the risk of SCD due to coronary heart disease (CHD) (P = 0.011) and the severity of autopsy-verified CAD (P = 0.026). Among GG homozygotes, hypertension was a major risk factor for SCD due to CHD [adjusted odds ratio (OR) 3.75 with 95% CI 1.78-7.91, P < 0.001] and hypertension also associated with larger coronary atherosclerotic plaque areas (P = 0.002) and the occurrence of complicated plaques (adjusted OR 8.38 with 95% CI 2.39-29.33, P < 0.001). Among C allele carriers, hypertension was not a significant risk factor for CHD-related SCD or CAD and did not associate with the development of coronary atherosclerotic plaques. According to gene expression analysis of atherosclerotic tissue samples obtained from live patients, hypertension also interacted significantly with IL-18 genotype affecting the expression of IL-18 (P = 0.030) mRNA and interferon-gamma mRNA (P = 0.004)., Conclusion: Hypertension interacts with IL-18 gene promoter -137 G/C polymorphism, affecting the risk of SCD and the development of coronary atherosclerosis.
- Published
- 2009
- Full Text
- View/download PDF
17. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
- Author
-
Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, and Lassila R
- Subjects
- Adenosine Monophosphate pharmacology, Adult, Aged, Aged, 80 and over, Aspirin pharmacology, Blood Platelets drug effects, Clopidogrel, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Platelet Aggregation drug effects, Ticlopidine pharmacology, Ticlopidine therapeutic use, Treatment Outcome, Angioplasty, Balloon, Coronary, Aspirin therapeutic use, Platelet Aggregation Inhibitors therapeutic use, Purinergic P2 Receptor Antagonists, Ticlopidine analogs & derivatives
- Abstract
Introduction: Large individual variability in clopidogrel responses has been reported. However, mechanisms of the non-responsiveness are unclear. Our aim was to study the extent of platelet inhibition at the receptor level by in vitro receptor antagonists of P2Y(12) (AR-C69931MX, cangrelor) and P2Y(1) (adenosine 3',5'diphosphate) in aspirin treated patients with coronary artery disease (CAD) prior to and after in vivo clopidogrel., Materials and Methods: 51 aspirin-treated (100 mg/day) patients participated. Blood was collected before and after administration of clopidogrel at 300 mg loading dose on day one, followed by 75 mg/d for four days. Aggregation in platelet-rich plasma was assessed., Results: In 20% of patients clopidogrel failed to inhibit platelet responses to ADP. These non-responders had also decreased sensitivity to an in vitro P2Y(12)-receptor antagonist compared with the responders (mean inhibition of aggregation 25 vs. 32%, difference of means 7% (95% CI 2-12%), P<0.02). Moreover, the P2Y(12)-receptor inhibition by in vivo clopidogrel correlated with the inhibition by in vitro ARMX measured prior to administration of clopidogrel. Neither P2Y(1)-receptor activity, thrombin generation while on aspirin nor basal platelet activity associated with clopidogrel responses., Conclusions: Concomitant aspirin and clopidogrel treatment failed to suppress platelet activity in 20% of patients. Non-responders to clopidogrel had decreased responses also to another ADP receptor antagonist, which suggests that the impaired response occurs at the level of P2Y(12)-receptor.
- Published
- 2009
- Full Text
- View/download PDF
18. Interactions of functional apolipoprotein E gene promoter polymorphisms with smoking on aortic atherosclerosis.
- Author
-
Viiri LE, Viiri KM, Ilveskoski E, Huhtala H, Mäki M, Tienari PJ, Perola M, Lehtimäki T, and Karhunen PJ
- Subjects
- Adult, Aged, Alleles, Apolipoprotein E2 genetics, Apolipoprotein E3 genetics, Apolipoprotein E4 genetics, Genetic Predisposition to Disease, Genotype, Haplotypes, Hep G2 Cells, Humans, Male, Middle Aged, Polymorphism, Genetic, Promoter Regions, Genetic, Aortic Diseases genetics, Apolipoproteins E genetics, Atherosclerosis genetics, Smoking
- Abstract
Background: Apolipoprotein E gene (APOE) interacts with environmental factors in defining risk for atherosclerosis. We studied whether the APOE epsilon2/epsilon3/epsilon4 genotype or APOE promoter polymorphisms -219G/T and +113G/C might interact with smoking on the development of fatty streaks. We also studied the previously unknown effects of +113G/C on transcriptional activity., Methods and Results: The fatty streak areas of aorta were measured morphometrically in subjects of the Helsinki Sudden Death Study. Within APOE epsilon3/epsilon3 subjects, there was a strong interaction between smoking and both -219G/T (P=0.009) and +113G/C (P=0.003) promoter polymorphisms on abdominal aorta fatty streak area: the -219T- and +113C-allele carriers had larger lesion areas compared with G/G (12.7% versus 5.9%, P=0.007; 12.9% versus 6.3%, P=0.010, respectively) within nonsmokers. Within smokers, the associations were inverse. Moreover, smoking increased the fatty streak area within -219G/G or +113G/G genotypes and -219G/+113G/epsilon3 haplotype carriers. Functional studies in reporter assay showed that in comparison with the +113G allele, the +113C allele had higher transcriptional activity and bound transcription factors from liver cell nuclear extract with significantly lower affinity., Conclusions: In middle-aged Finnish men with APOE epsilon3/epsilon3 genotype, the APOE promoter polymorphisms -219G/T and +113G/C interact with smoking in modulating aortic atherosclerosis. The +113G/C polymorphism has an effect on transcriptional activity.
- Published
- 2008
- Full Text
- View/download PDF
19. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease.
- Author
-
Nieminen T, Kähönen M, Viiri LE, Grönroos P, and Lehtimäki T
- Subjects
- Cholesterol, LDL genetics, Humans, Polymorphism, Genetic, Apolipoproteins E genetics, Cholesterol, LDL blood, Coronary Disease genetics, Coronary Disease prevention & control, Pharmacogenetics
- Abstract
A non-optimal plasma concentration of lipids is among the major modifiable risk factors of atherosclerosis. Therefore, the prevention of cardiovascular disease by means of lipid-lowering therapy with statins and other agents is of great importance for patient groups where a lifestyle change, for example, diet modification, does not lead to adequately reduced lipid levels. The response of low-density-lipoprotein cholesterol (LDL-C) levels to statin therapy is highly variable. This is partly attributed to hereditary variation in genes involved in pharmacokinetics, pharmacodynamics and lipid metabolism. The pharmacogenetics of lipid-lowering therapy have been investigated for more than 40 different genes. The gene for apolipoprotein E (APOE) has been the most frequently studied, particularly regarding the epsilon2/epsilon3/epsilon4 polymorphism. Those with the epsilon4 allele seem to have the poorest and those with the epsilon2 allele the strongest response to statins with regards to LDL-C levels. In addition, the epsilon2 carriers may reach the LDL-C treatment goals more frequently than epsilon4 carriers. Few studies have investigated the interaction of the APOE epsilon2/epsilon3/epsilon4 polymorphism and lipid-lowering therapy in relation to the course of coronary heart disease; the results are contradictory and so far inconclusive. This review summarizes the pharmacogenetic findings related to the influence of APOE gene variation on lipid responses and the prevention of coronary heart disease during lipid-lowering therapy.
- Published
- 2008
- Full Text
- View/download PDF
20. Neuropeptide Y signal peptide Pro7 substitution protects against coronary artery atherosclerosis: the Helsinki Sudden Death Study.
- Author
-
Ilveskoski E, Viiri LE, Mikkelsson J, Pörsti I, Lehtimäki T, and Karhunen PJ
- Subjects
- Adult, Aged, Autopsy, Coronary Artery Disease pathology, Gene Expression Regulation, Genotype, Humans, Leucine chemistry, Male, Middle Aged, Proline chemistry, Risk, Coronary Artery Disease genetics, Neuropeptide Y metabolism, Polymorphism, Genetic, Protein Sorting Signals genetics
- Abstract
Objective: Neuropeptide Y (NPY) has a single nucleotide polymorphism at T1128C, leading to change of Leucine7 to Proline7. The Leu7Pro substitution has been linked to cardiovascular disease, but it is unknown whether the Pro7 allele is associated with increased or decreased risk of coronary heart disease (CHD). The aim of the present study was to investigate the association of the Leu7Pro polymorphism with coronary atherosclerosis and its consequences., Methods: We studied two autopsy series comprising 700 unselected middle-aged Caucasian men (Helsinki Sudden Death Study) who had died suddenly out of hospital. Areas of coronary artery atherosclerosis, narrowings of coronary arteries, and presence of myocardial infarction and/or coronary thrombosis were analyzed. All information including CHD risk factor data was obtained from 410 men., Results: NPY genotype distribution was Leu7/Leu7=89.8%, Leu7/Pro7=10.0% and Pro7/Pro7=0.2%). Although the Pro7 allele was associated with reported hypertension (p=0.03), the men carrying Pro7 allele had lower area of fatty streaks (p=0.04), fibrotic lesions (p=0.07) and complicated lesions (p=0.004) in the left anterior descending (LAD) coronary artery and also less severe LAD narrowings (p=0.04) than men with the Leu7/Leu7 genotype. Supporting a protective role for the Pro7 allele against atherosclerosis, only 1 out of 46 men (2%) with coronary thrombosis carried the Pro7 allele (p=0.08 compared to men dying of other causes). This association weakened (OR 0.18 for Pro7 versus Leu7/Leu7, p=0.16) when adjusted for all available CHD risk factors., Conclusions: NPY Pro7 substitution protects middle-aged men from coronary artery atherosclerosis and might decrease the risk of acute coronary events.
- Published
- 2008
- Full Text
- View/download PDF
21. Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis.
- Author
-
Abboud S, Viiri LE, Lütjohann D, Goebeler S, Luoto T, Friedrichs S, Desfontaines P, Gazagnes MD, Laloux P, Peeters A, Seeldrayers P, Lehtimaki T, Karhunen P, Pandolfo M, and Laaksonen R
- Subjects
- Aged, Autopsy, Brain Ischemia pathology, Case-Control Studies, Genetic Variation, Humans, Intracranial Arteriosclerosis pathology, Male, Middle Aged, Stroke pathology, Apolipoproteins E genetics, Brain Ischemia genetics, Intracranial Arteriosclerosis genetics, Polymorphism, Single Nucleotide genetics, Promoter Regions, Genetic genetics, Stroke genetics
- Abstract
The apolipoprotein E (APOE) epsilon4 allele is associated with elevated cholesterol and risk of atherosclerosis. However, its role in ischemic stroke (IS) remains controversial. We investigated a possible link between IS or the severity of intracranial atherosclerosis and the APOE promoter polymorphisms -219G/T and +113G/C, involved in regulating APOE transcription. We genotyped subjects from a multicentric Belgian case-control study, including 237 middle-aged patients with IS due to small- or large-vessel atherosclerotic stroke and 326 ethnicity- and gender-matched controls and a Finnish autopsy series of 1004 non-stroke cases, who had received a quantitative score of atherosclerosis in the circle of Willis. The APOE epsilon4+ genotype did not associate with IS, but was related to more severe intracranial atherosclerosis score in men (5.4 vs 4.6, P=0.044). Within the most common APOE epsilon3/epsilon3 genotype group, the risk of IS associated with the G-allele of the tightly linked -219G/T (OR=6.2; 95% CI: 1.6-24.3, P=0.009) and +113G/C (OR=7.1; 95% CI: 1.7-29.9, P=0.007) promoter polymorphisms. There was no difference in the severity of intracranial atherosclerosis between -219G/G genotype carriers and non-carriers. This study suggests a multifaceted role of apoE on the risk of cerebrovascular diseases. The APOE epsilon4+ genotype did not predict the risk of IS but was associated with severity of subclinical intracranial atherosclerosis in men on the autopsy study. In contrast, the promoter variants were significant predictors of IS, suggesting that quantitative rather than qualitative variation of apoE is related to IS.
- Published
- 2008
- Full Text
- View/download PDF
22. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: the Helsinki Sudden Death Study.
- Author
-
Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Pessi T, Hurme M, and Lehtimäki T
- Subjects
- Adult, Aged, Autopsy, Coronary Disease mortality, Finland epidemiology, Gene Frequency, Heterozygote, Homozygote, Humans, Male, Middle Aged, Risk Factors, Coronary Disease genetics, Death, Sudden, Cardiac etiology, Interleukin-18 genetics, Polymorphism, Genetic, Promoter Regions, Genetic
- Abstract
Objective: The increased plasma concentrations of pro-atherogenic and cardiomyocyte hypertrophic cytokine interleukin 18 (IL-18) predict mortality in patients with coronary heart disease (CHD) in addition to predicting the outcome of heart failure. The IL-18 gene has a functional -137G/C polymorphism (rs187238) in the promoter region. The C allele carriage is associated with attenuated IL-18 production. The effect of IL-18 genotype on SCD is unknown. We studied the association of the IL-18 gene -137G/C polymorphism with the occurrence of sudden cardiac death (SCD)., Methods: Using the TaqMan 5' nuclease assay, we genotyped two independent consecutive and prospective autopsy series which were included in the Helsinki Sudden Death Study., Results: Of the 663 men, 359 (54.1%) had the wild-type GG-genotype, 261 (39.4%) were heterozygotes (CG) and 43 (6.5%) were CC homozygotes. Compared to the GG homozygotes, the C allele carriers (i.e. subjects having CC or CG genotypes) had a lower adjusted risk for SCD from any cause (odds ratio [OR] 0.49; 95% confidence interval [CI], 0.31-0.77, p=0.002), for SCD due to CHD (OR 0.51; 95% CI, 0.32-0.82, p=0.005), and for SCD caused by non-coronary heart diseases (OR 0.34; 95% CI 0.13-0.90, p=0.030)., Conclusion: IL-18 promoter -137G/C polymorphism, which regulates the expression of IL-18, is an important predictor of SCD from any cause as well as SCD in patients with and without underlying CHD.
- Published
- 2008
- Full Text
- View/download PDF
23. Association of the apolipoprotein E gene, its promoter polymorphisms and haplotypes with depressive symptoms. The Cardiovascular Risk in Young Finns Study.
- Author
-
Elovainio M, Puttonen S, Pulkki-Råback L, Kivimaki M, Viiri LE, Lehtimaki T, Karhunen P, Viikari J, Raitakari OT, and Keltikangas-Jarvinen L
- Subjects
- Adult, Analysis of Variance, Cohort Studies, Community Health Planning, Female, Finland epidemiology, Humans, Male, Retrospective Studies, Risk Factors, Young Adult, Apolipoproteins E genetics, Depression genetics, Genetic Predisposition to Disease, Haplotypes genetics, Polymorphism, Genetic genetics, Promoter Regions, Genetic genetics
- Abstract
Objectives: Evidence on apolipoprotein E (APOE) gene as a vulnerability factor for depression is mixed. Polymorphisms of the APOE gene regulatory region may serve as additional explanatory factors, as they help in explaining variation of depressive symptoms within the APOE epsilon2/epsilon3/epsilon4 genotype groups. In this study, the associations of the APOE gene promoter polymorphisms -219G/T and +113G/C and their haplotypes with depressive symptoms were examined., Methods: The data is from a subpopulation of 660 young adults (24-39 years old) of the ongoing population-based Cardiovascular Risk in Young Finns Study. Depressive symptoms were assessed by a revised version of Beck's Depression Inventory. Clinical screening assessed lipid levels and other known physiological and behavioral risk factors for depressive symptoms., Results: The APOE epsilon4 allele was not related to depressive symptoms. Similarly, no statistically significant associations were found between the APOE gene promoter -219G/T and +113G/C polymorphisms and depressive symptoms. Within theAPOE epsilon3/epsilon3 genotype subgroup (n = 373), carriers of both -219G/+113C and -219T/+113G haplotypes (GC/TG) had higher depressive symptoms compared to noncarriers of these haplotypes (2.52 vs. 1.98; p = 0.002). This relationship persisted after separate adjustments for various risk factors including sex, age, LDL cholesterol, HDL cholesterol, triglycerides, total cholesterol, C-reactive protein, systolic blood pressure, body mass index and alcohol consumption., Conclusions: Our results suggest that the APOE gene does not predispose carriers to depressive symptoms among healthy young adults. However, the promoter haplotype GC/TG may elevate the risk of depressive symptoms., (Copyright 2008 S. Karger AG, Basel.)
- Published
- 2008
- Full Text
- View/download PDF
24. The hepatic lipase gene C-480T polymorphism in the development of early coronary atherosclerosis: the Helsinki Sudden Death Study.
- Author
-
Fan YM, Lehtimäki T, Rontu R, Ilveskoski E, Goebeler S, Kajander O, Mikkelsson J, Viiri LE, Perola M, and Karhunen PJ
- Subjects
- Adult, Aged, Autopsy methods, Humans, Male, Middle Aged, Risk Factors, Coronary Artery Disease genetics, Death, Sudden etiology, Lipase genetics, Polymorphism, Genetic genetics
- Abstract
Background: The T allele of the hepatic lipase (HL) C-480T polymorphism was previously found to be associated with lower post-heparin plasma HL activity, atherosclerosis and risk of coronary artery disease. We studied the association of HL C-480T polymorphism with the extent of atherosclerosis at vessel-wall level in an autopsy series of middle-aged men., Materials and Methods: An autopsy cohort of 700 Caucasian Finnish men aged 33-70 years (mean 53 years), which comprised two autopsy series, collected 10 years apart during 1981-82 and 1991-92, were analysed. Areas of coronary wall covered with fatty streaks and fibrotic and complicated lesions were measured using computer-assisted planimetry and related to HL C-480T genotypes (CC, CT, and TT)., Results: There was a significant age-by-genotype interaction on the mean percentage area of fatty streaks (P = 0.01). The HL C-480T polymorphism was a significant explanatory factor for fatty streak area in men under 53 years of age with or without age, body mass index, hypertension, diabetes, smoking, alcohol consumption, apolipoprotein E genotype, and series number as covariates. Men carrying the TT genotype had two times larger areas of fatty streaks compared to the CC carriers (8.8% vs. 4.3%, P = 0.009). However, this association disappeared in men over 53 years. The areas of more advanced atherosclerotic lesions did not vary significantly among the genotype groups., Conclusions: Our results suggest that the HL C-480T polymorphism affects the formation of early coronary atherosclerotic lesions in men in their early middle age.
- Published
- 2007
- Full Text
- View/download PDF
25. Relations of APOE promoter polymorphisms to LDL cholesterol and markers of subclinical atherosclerosis in young adults.
- Author
-
Viiri LE, Raitakari OT, Huhtala H, Kähönen M, Rontu R, Juonala M, Hutri-Kähönen N, Marniemi J, Viikari JS, Karhunen PJ, and Lehtimäki T
- Subjects
- Adolescent, Adult, Analysis of Variance, Atherosclerosis blood, Atherosclerosis genetics, Child, Child, Preschool, Cholesterol blood, Cholesterol, HDL blood, Female, Gene Frequency, Genotype, Haplotypes genetics, Humans, Longitudinal Studies, Male, Models, Biological, Apolipoproteins E genetics, Atherosclerosis pathology, Biomarkers blood, Cholesterol, LDL blood, Polymorphism, Single Nucleotide genetics, Promoter Regions, Genetic genetics
- Abstract
The common apolipoprotein E (apoE) gene (APOE) epsilon2/epsilon3/epsilon4 polymorphism explains part of serum lipid variation, and polymorphisms in the APOE promoter region have been proposed to participate in the regulation of serum lipid levels within the most common APOE epsilon3/epsilon3 genotype group. We determined APOE -219G/T and +113G/C promoter genotypes and estimated APOE haplotypes in 525 participants of the Cardiovascular Risk in Young Finns Study. We studied the associations of the APOE promoter polymorphisms and their haplotypes with cross-sectional and longitudinal serum lipid and apolipoprotein concentrations as well as with flow-mediated dilatation (FMD), carotid artery compliance (CAC), and intima-media thickness (IMT) within the APOE epsilon3/epsilon3 carriers. We found no significant association between the APOE promoter genotypes and serum lipids [low density lipoprotein-cholesterol (LDL-C), HDL-C, and triglycerides], apolipoproteins (apoA-I and apoB), or brachial artery FMD, CAC, or carotid IMT in either men or women. In longitudinal analyses in males, the carriers of heterozygous genotypes (-219G/T or +113G/C) and, furthermore, carriers of the -219T/+113C/epsilon3 haplotype had significantly higher LDL-C and total cholesterol concentrations throughout the 21 year follow-up period compared with homozygous G allele carriers or noncarriers of the -219T/+113C/epsilon3 haplotype. Such associations were not found in females. In summary, the APOE promoter polymorphisms -219G/T and +113G/C as well as their haplotype are associated with longitudinal changes in LDL-C and total cholesterol concentrations in young Finnish males but do not seem to be major determinants for FMD, CAC, or carotid IMT in males or females.
- Published
- 2006
- Full Text
- View/download PDF
26. Toll-like receptor 4 polymorphism is associated with coronary stenosis but not with the occurrence of acute or old myocardial infarctions.
- Author
-
Hernesniemi J, Lehtimäki T, Rontu R, Islam MS, Eklund C, Mikkelsson J, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Hurme M, and Karhunen PJ
- Subjects
- Acute Disease, Comorbidity, Coronary Stenosis epidemiology, Coronary Stenosis pathology, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac pathology, Finland epidemiology, Humans, Male, Middle Aged, Myocardial Infarction epidemiology, Myocardial Infarction pathology, White People genetics, Coronary Stenosis genetics, Death, Sudden, Cardiac etiology, Myocardial Infarction genetics, Polymorphism, Genetic, Toll-Like Receptor 4 genetics
- Abstract
Objective: Atherosclerosis is considered to be a chronic inflammatory disease. Toll-like receptor 4 (TLR-4), a key mediator in activating inflammatory cascade, has an A-to-G functional polymorphism that changes aspartic acid to glycine at position 299. TLR-4 is activated by, for example, lipopolysaccharides. The purpose of this study was to investigate the role of a common Asp299Gly polymorphism of the TLR-4 gene in atherosclerosis., Material and Methods: The study comprised autopsy material from 657 men (the Helsinki Sudden Death Study; mean age 53, range 33-70 years)., Results: Fewer G-allele carriers had 3-vessel coronary artery disease compared with AA homozygotes (OR 0.32; 95 % CI, 0.12-0.88, p = 0.027), and they also had a lower mean value for maximal coronary stenosis (p = 0.019). TLR-4 polymorphism was not significantly associated with the occurrence of acute or old myocardial infarction (MI)., Conclusions: The G allele of the TLR-4 gene, which is associated with a lower inflammation response, was associated with a lower risk of coronary stenosis but not with the occurrence of MI and hence is not a major factor in the development of coronary atherosclerosis.
- Published
- 2006
- Full Text
- View/download PDF
27. The association of the apolipoprotein E gene promoter polymorphisms and haplotypes with serum lipid and lipoprotein concentrations.
- Author
-
Viiri LE, Loimaala A, Nenonen A, Islam S, Vuori I, Karhunen PJ, and Lehtimäki T
- Subjects
- Adult, Arteriosclerosis blood, Cholesterol, HDL blood, Cholesterol, LDL blood, Finland, Gene Frequency, Haplotypes, Humans, Male, Promoter Regions, Genetic genetics, Apolipoproteins E genetics, Arteriosclerosis genetics, Cholesterol, VLDL blood, Polymorphism, Genetic, Triglycerides blood
- Abstract
Background: Apolipoprotein E (ApoE) is known to modulate lipoprotein transport and metabolism. The common APOE epsilon2/epsilon3/epsilon4 polymorphism explains part of the variation in plasma cholesterol levels. Polymorphisms of the APOE gene regulatory region are suggested to be involved in explaining variation of lipoprotein levels within the APOE epsilon2/epsilon3/epsilon4 genotypes., Objectives: To study the associations of the APOE gene promoter polymorphisms -219G/T and +113G/C and their haplotypes with serum lipid and lipoprotein concentrations, especially within the most common APOE epsilon3/epsilon3 genotype group., Subjects and Methods: From 219 middle-aged Finnish men, APOE genotypes were determined and haplotypes estimated. Plasma lipoproteins were isolated by ultracentrifugation and their lipids were measured., Results: The studied APOE promoter polymorphisms and haplotypes associated with certain lipid variables independently of the APOE epsilon2/epsilon3/epsilon4 genotype. Within the APOE epsilon3/epsilon3 group, both -219G/G and +113G/G genotypes associated statistically significantly with higher levels of very low-density lipoprotein (VLDL) cholesterol, apoB and triglycerides, and tended to associate with lower HDL-cholesterol concentrations than the other genotypes. Compared with the -219T/+113C/epsilon3 haplotype, the more common -219G/+113G/epsilon3 haplotype was found more frequently among the group having high (over median) VLDL-cholesterol and triglyceride concentrations (OR 2.6, p<0.001 and OR=2.1, p=0.009, respectively)., Conclusions: In addition to the APOE epsilon2/epsilon3/epsilon4 polymorphism, the promoter polymorphisms -219G/T and +113G/C as well as their haplotype modulate lipid and lipoprotein concentrations in middle-aged Finnish men.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.